Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the addition of Camonsertib to radiation therapy for recurrent head and neck squamous cell carcinoma (not yet recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Camonsertib

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING